Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Melanoma

E2F transcription factor 1 (E2F1); tumor protein p73 (TP73; p73)

Cell culture and mouse studies suggest combining methotrexate with an antifolate prodrug could help treat melanoma. In a panel of human melanoma cell lines with different oncogenic mutations, including lines with acquired resistance to BRAF and MEK inhibitors, methotrexate plus the antifolate prodrug 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin (TMECG) upregulated E2F1 and p73 and decreased growth compared with either compound alone. In a mouse xenograft model for melanoma, the combination decreased tumor growth compared with either treatment alone. Next steps include conducting pharmacokinetic and toxicology studies of TMECG.

SciBX 6(28); doi:10.1038/scibx.2013.717
Published online July 25, 2013

Patent application filed; available for licensing

Saéz-Ayala, M. et al. Cancer Cell;
published online June 20, 2013;
doi:10.1016/j.ccr.2013.05.009
Contact: José Neptuno Rodríguez-López, University of Murcia, Murcia, Spain
e-mail:
neptuno@um.es
Contact: Colin R. Goding, University of Oxford, Oxford, U.K.
e-mail:
colin.goding@ludwig.ox.ac.uk